Cardiovascular Disease

The NDA for daprodustat, a novel investigational agent, is based on data from pivotal ASCEND program clinical trials.

Patients who received a low-dose 3-drug combination pill achieved time at BP target of 64% vs the usual care group result of 43% in a post-hoc analysis of TRIUMPH.

SuperWIN trial findings suggest the future of successful health care depends on harnessing familiar, community- based resources to maintain health and deliver care.

Coprincipal investigator Steen highlights the first-of-its kind study and the findings—local in-store dietitian counseling/feedback, nutrition education, and online shopping savvy improve food choices, health metrics.

Obesity significantly increased the risk of heart failure among women who experienced menopause at age ≥55 years in a new study.

Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.

The FDA clearance for the FitBit algorithm will provide another widely tested tool for patient and clinicians to help identify arrhythmias earlier and avoid severe cardiocerebrovascular events.

ACC 2022: Use of antihypertensive therapy in pregnant women was associated with better pregnancy outcomes, such as preeclampsia and fetal or neonatal death.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.

The new HF guidelines prioritize primary prevention, revise disease stages to encourage early intervention, and now include SGLT2i as guideline-directed medical therapy.

ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.

ACC 2022. An EHR alert tailored to prompt clinicians to check guideline-directed medical therapy for individual HF patients was integrated carefully into clinical workflow.

ACC 2022. SODIUM-HF secondary findings, however, showed improvement in NYHA HF class and in QOL in the dietary intervention group.

ACC 2022. Findings suggest that more attention to monitoring cognitive functioning after a myocardial infarction is needed.

The higher dose of the GLP-1 analogue allows more flexibility for patients with T2D needing to intensify treatment, says manufacturer Novo Nordisk.

ACC 2022. Can a couple of cups of coffee per day keep cardiovascular disease at bay? Findings from 3 new studies shed light.

ACC 2022. Approximately 5% of hospitalizations for acute MI in the state were found attributable to elevated levels of traffic noise.

ACC 2022. ACC late-breaking clinical trial sessions begin Sat, April 2, 2022. Our short slide shows highlight the studies of interest to primary care clinicians.

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

ACC 2022. Large study of US adults showed those with depression following MI were 50% more likely to experience a stroke than those who did not have depression.

ACC 2022. Exercise lowers CVD risk in part by reducing the same neurobiologic activity associated with depression and anxiety, according to study authors.

ACC 2022. A new systematic review suggests skin melanin content may impede accurate recording of heart rate and rhythm by wearable devices.

ACC.22: Findings from 3 studies show drinking 2-3 cups of coffee per day is associated with a reduced risk of CVD, abnormal heart rhythms, and mortality.

Cardiovascular-health-focused company Eko redesigned its app to enable screening for cardiovascular disease within seconds during a physical exam.

The phase 3 EMPA-KIDNEY clinical trial had just met prespecified criteria for positive efficacy when the study's Independent Data Monitoring Committee recommended the early halt.

A new meta-analysis questions the science demonstrating the link between statin-induced LDL-C lowering and improved CV, all-cause outcomes.

Men were more likely to experience sudden cardiac death than women across all age groups in a new nationwide study.

The direct oral anticoagulant was associated with a lower rate of rehospitalization for VTE among patients extending anticoagulation beyond 90 days, investigators report.

The increased risk of CVD was observed even in young adults with a serious mental illness, according to an analysis of nearly 600 000 US adults.